Herceptin® (trastuzumab) par voie sous-cutanée : une mini révolution ? Étude pharmaco-économique
Abstract
Herceptin(®) injected by intravenous (IV) is one of the key treatment of breast cancer HER2+. The improvement of galenic form allowed a new way of administration, the sub-cutaneous way (SC), authorized by EMEA in 2013. This new way enables a 5-minute infusion, a fixed dose and a fixed volume of preparation. On 2012, saving-time and financial impacts were calculated by extrapolation of the IV way in a cancer treatment center. The study showed a preparing time-saving of 7.5min/loading dose and of 6.5min/maintenance dose, and a nurse time-saving of 4.5min/loading dose and 4.25min/maintenance dose. Moreover, it can be added a saving of consumable of 13,31€ per injection in case of monotherapy. The SC leads to a new adaptation and reorganization in the preparation of monoclonal antibodies and day hospitals.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Significant cost savings were also seen in various other countries.
“Significant cost savings were also seen in various other countries [7, 8, 44–47].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [45]
Cites
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,039 · see citing works
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
Sliwkowski, M. X., Schaefer, G., Akita, R. W., Lofgren, J. A., Fitzpatrick, V. D., Nuijens, A., FENDLY, B. M., Cerione, R. A., VANDLEN, R. L., & Carraway, K. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36676-0 · Cited by 644 · see citing works
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L. K., Kaptain, S., Bach, A. M., Panageas, K. S., Arroyo, C. D., Valero, V., Currie, V. E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 546 · see citing works
Pivot, X., Gligorov, J., Müller, V., Barrett-Lee, P., Verma, S., Knoop, A., Curigliano, G., Semiglazov, V., López-Vivanco, G., Jenkins, V., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70383-8 · Cited by 230 · see citing works
Davies, A., Merli, F., Mihaljevic, B., Siritanaratkul, N., Solal-Céligny, P., Barrett, M., Berge, C., Bittner, B., Boehnke, A., McIntyre, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70005-1 · Cited by 114 · see citing works
Cancers du sein : évolution des grands concepts thérapeutiques
Roche, H. H. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1805 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447 · see citing works
Chen, X., Wang, M., Yang, X., Wang, Y., Yu, L., Sun, J., & Ding, J. (2019) · Theranostics · doi:10.7150/thno.36514 · Cited by 126 · see citing works
Lopez-Vivanco, G., Salvador, J., Diez, R., López, D., De Salas-Cansado, M., Navarro, B., & De la Haba-Rodríguez, J. (2017) · Clinical and Translational Oncology · doi:10.1007/s12094-017-1684-4 · Cited by 54 · see citing works
Pivot, X. B., Verma, S., Fallowfield, L. J., Müller, V., Lichinitser, M., Jenkins, V. A., Muñoz, A. S., Machackova, Z., Osborne, S., & Gligorov, J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.08.019 · Cited by 52 · see citing works
O'Brien, G. L., O'Mahony, C., Cooke, K., Kinneally, A., Sinnott, S.-J., Walshe, V., Mulcahy, M., & Byrne, S. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.01.011 · Cited by 29 · see citing works
Rojas, L., Muñiz, S., Medina, L., Peña, J., Acevedo, F., Pinto, M. P., & Sanchez, C. (2020) · PLOS ONE · doi:10.1371/journal.pone.0227961 · Cited by 23 · see citing works
Fargier, E., Ranchon, F., Huot, L., Guerre, P., Safar, V., Dony, A., Hequet, N., Bachy, E., Savouroux, S., Fronteau, C., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-017-3147-y · Cited by 20 · see citing works
Changra, H. O., & Robles-Díaz, J. F. (2021) · Journal of Healthcare Quality Research · doi:10.1016/j.jhqr.2021.10.008 · Cited by 9 · see citing works
Landeiro, L. C. G., Martins, T. D. C., Grigolon, R. B., Monteiro, I., Balardin, J. B., Padilha, E., Amorim, G. L. D. S., & Stefani, S. D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1338546 · Cited by 7 · see citing works
Elsamany, S. A., Elsisi, G. H., Hassanin, F., & Jafal, M. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1860024 · Cited by 7 · see citing works
Pailler, C., Chapot, T., Softa, S., Gandrille, N., Ruiz, D., Mathieu, S., & Delaloge, S. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.10.005 · Cited by 6 · see citing works
Despiau, F., Zagala, Y., Delord, J.-P., Montastruc, M., Lacaze, J.-L., Ferrand, R., & Bombail, M. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.08.007 · Cited by 4 · see citing works
Barat, É., Arrii, M., Soubieux, A., Daouphars, M., Varin, R., & Tilleul, P. R. (2023) · The Breast · doi:10.1016/j.breast.2023.103588 · Cited by 3 · see citing works
Safety of pertuzumab and trastuzumab administered in a single infusion bag in breast cancer
de Coucy, A., Ollivier, J., Malifarge, L., Deppenweiler, M., Donamaria, C., & Lortal, B. (2020) · European Journal of Oncology Pharmacy · doi:10.1097/op9.0000000000000026 · Cited by 1 · see citing works
Deppenweiler, M., Teytaud, M., Stein, P., Donamaria, C., & Lortal, B. (2021) · European Journal of Oncology Pharmacy · doi:10.1097/op9.0000000000000029
- Authors
- Lieutenant, V., Toulza, É., Pommier, M., & Lortal-Canguilhem, B.
- Affiliations
- Institut Bergonié (FR)
- Venue
- Bulletin du Cancer
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 102
- Issue
- 3
- Pages
- 270-276
- ISSN
- 0007-4551 (ISSN-L)
- OpenAlex
- W2091276904
- Cited by
- 15
- References
- 6
- Citations by year
- 2024: 1 · 2023: 1 · 2021: 2 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 4
- FWCI
- 4.83
- Type
- journal article
- Language
- fr
- Open access
- closed
- Locations
- Bulletin du Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Keywords
- trastuzumab, subcutaneous administration, HER2-positive breast cancer, pharmacoeconomics, fixed-dose formulation, monoclonal antibodies, day hospital, consumable costs
- MeSH terms
- Trastuzumab, Administration, Cutaneous, Antineoplastic Agents, Breast Neoplasms, Drug Administration Schedule, Female, Humans, Time Factors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
